Name (Synonyms) | Correlation | |
---|---|---|
drug824 | Eculizumab Wiki | 0.71 |
drug1441 | Matching Placebo Wiki | 0.71 |
drug2067 | Remdesivir Wiki | 0.26 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
Description: Proportion of subjects alive at Day 28 who are not hospitalized or if hospitalized are free of respiratory failure
Measure: Number of subjects not hospitalized or, if hospitalized, free of respiratory failure Time: Day 0 to Day 28Description: Number of Adverse Events (AEs) and number & percentage of subjects experiencing AEs after administration of the first dose of study drug
Measure: Adverse Events Time: Day 0 to Day 56Description: Change in NIAID 8-point ordinal scale, where 1=Death and 8=Not hospitalized, no limitations on activities
Measure: National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale Time: Day 0 to Day 28Description: Duration of fever
Measure: Temperature Time: Day 0 to Day 37Description: Number of deaths
Measure: Death Time: Day 0 to Day 56Description: Need and duration of mechanical ventilation
Measure: Mechanical ventilation Time: Day 0 to Day 56Description: Duration of vasopressor support
Measure: Vasopressor Support Time: Day 0 to Day 56Description: Duration of oxygen therapy via mechanical ventilation, face mask or nasal cannula
Measure: Oxygen Therapy Time: Day 0 to Day 37Description: Time to cessation of viral shedding based on absence of SARS-CoV-2 in a PCR based COVID-19 test
Measure: Cessation of Viral Shedding Time: Day 0 to Day 37Description: Change in SpO2/FiO2
Measure: Change in Oxygen Saturation/Fraction of Inspired Oxygen Time: Day 0 to Day 37